Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cor.Sync has developed an innovative point-of-care diagnostic device that delivers rapid, ultrasensitive quantitative troponin results at the bedside. The technology uses patented surface plasmon resonance sensors analyzed by artificial intelligence. Preliminary data show a coefficient of variation (~6%) comparable to laboratory gold standards. The device aims to speed up heart attack diagnosis in emergency settings, potentially saving lives and reducing healthcare costs. Clinical studies are expected to start later in 2025; regulatory approval and commercialization are anticipated after successful trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cor.Sync.